Immunogenicity and Safety of NVX-CoV2373 as a Homologous or Heterologous Booster: A Phase 3 Randomized Clinical Trial in Adults

2023-03-20 infectious diseases Title + abstract only

Show abstract

BackgroundTo combat the SARS-CoV-2 pandemic, multiple vaccines using different manufacturing platforms have been developed, including NVX-CoV2373 (an adjuvanted recombinant protein vaccine). As SARS-CoV-2 variants have emerged, some of which evade vaccine-induced immunity, introduction of vaccine booster doses has become critical. Employing different vaccine types for primary series vaccination and boosting could expand vaccine coverage and access. This study assessed whether NVX-CoV2373 would i...

Immunogenicity and Safety of NVX-CoV2373 as a Homologous or Heterologous Booster: A Phase 3 Randomized Clinical Trial in Adults

Predicted journal destinations